Not a slow fade — a decade of hormonal turbulence

Something happens in the mid-40s that catches most women off guard. Periods become unpredictable. Sleep fractures at 3 a.m. The mind fogs over in meetings. And the standard explanation — "your oestrogen is dropping" — doesn't quite account for the intensity or the chaos.

The picture is more turbulent than that. Oestrogen in perimenopause does not slide gently downward. It surges and crashes without warning, sometimes reaching peak levels before plummeting — the rollercoaster that baffles both the women experiencing it and, often, the clinicians they consult. Meanwhile, the pituitary gland raises its output of FSH and LH in a bid to push increasingly unresponsive ovaries into action. The ovaries respond erratically, amplifying the chaos further. This transition typically spans three to four years from the mid-40s, but for some women it extends to a full decade.

Around 80–90% of women carry some symptom burden during this window. It is a near-universal disruption of the body's internal chemistry — not a quiet winding-down.

That framing matters. Regeneration by Design, the framework developed by Professor Paul Lee — an orthopaedic surgeon and medical engineer with over two decades of clinical and research experience — treats the body's internal chemical environment as something active, dynamic, and designable. Perimenopause is one of the clearest demonstrations of why that lens is worth borrowing: this is not a system running out of fuel, but a system in flux.

Why oestrogen and progesterone fall apart at different speeds

Progesterone's story is simpler — and that simplicity is where the trouble begins.

The hormone is produced primarily in the second half of the menstrual cycle, after ovulation. No ovulation, no progesterone signal. As cycles become irregular in the mid-40s, ovulation is increasingly skipped, and progesterone levels fall correspondingly — consistently and early in the transition, long before oestrogen begins any sustained decline.

Oestrogen's trajectory is the opposite of neat. Rather than tapering, it surges and collapses unpredictably, sometimes spiking above premenopausal norms before crashing. The result is a seesaw that has lost one of its riders: progesterone falls away while oestrogen remains volatile. This is the state known as relative oestrogen dominance — not an absolute excess of oestrogen, but an imbalance between two hormones designed to counterbalance each other. The distinction matters, because oestrogen levels during this phase are not consistently high; they simply lack progesterone's steadying influence.

That imbalance has recognisable consequences. Heavy or irregular periods, breast tenderness, fluid retention, heightened anxiety, and fragmented sleep are all characteristic of this hormonal state — and for many women they arrive before oestrogen has even begun its eventual decline, which is why symptoms can seem paradoxically intense while periods are still occurring.

Meanwhile, the pituitary gland pushes FSH and LH progressively higher in its attempt to coax a response from increasingly unresponsive ovaries. A rising FSH reading is typically the first laboratory signal that the transition is under way — one concrete anchor in an otherwise erratic picture, and a useful starting point for anyone trying to understand what their internal environment is actually doing.

Brain chemistry, mood and the neuroscience of brain fog

Forgetting a word mid-sentence, walking into a room and immediately losing the thread, feeling a low irritability that has no clear cause — these are among the most disorienting features of the perimenopausal years. They are also among the most readily dismissed, by clinicians and by the women experiencing them. The neuroscience tells a different story.

The most direct pathway runs through serotonin. Oestrogen actively modulates serotonin synthesis, and when it becomes volatile or falls, serotonin production drops with it. Serotonin governs not just mood but emotional regulation, impulse control, and the coherence of cognitive function. Disrupting its supply is not a background effect; it is a direct intervention in the brain's operating environment — a chemical event, not a psychological one.

What PET neuroimaging adds is even more arresting. A study in healthy midlife women found that oestrogen receptor density in oestrogen-regulated brain networks increases progressively over the menopause transition, and that higher receptor density correlates with poorer memory performance and predicts self-reported mood and cognitive symptoms. The brain is not a passive observer of hormonal change; it is actively remodelling its own sensitivity in real time, trying to compensate for a shifting signal.

A second, independent pathway converges on the same symptoms. As progesterone falls, sleep architecture deteriorates — the deep, restorative phases that underpin memory consolidation and emotional recovery are eroded. Melatonin production also declines during this period, amplifying circadian disruption. The outcome of both routes is the same: difficulty concentrating, blunted mood, cognitive friction that compounds through the day.

Regeneration by Design frames the brain explicitly as part of the body's internal environment — not a separate system, but one that responds to the same hormonal and neurochemical signals. Managing those signals is where meaningful support begins.

Metabolism, the gut and what the scales won't show

Many women notice their body composition shifting — particularly towards the abdomen — despite no meaningful change in diet or exercise. That observation is chemically coherent rather than imagined.

Oestrogen plays a direct role in insulin production, glucose uptake, and fat distribution. As it becomes volatile during perimenopause, insulin resistance tends to worsen beyond what ageing alone accounts for — creating a metabolic environment that shifts independently of caloric intake.

A 2026 study adds an emerging dimension. Perimenopausal ovarian decline appears to disrupt peripheral serotonin homeostasis in a way that impairs hepatic insulin signalling entirely independently of body weight or fat accumulation — a gut–liver serotonergic axis that standard measurements cannot capture. This is research-stage science, but it points to a metabolic vulnerability that scales and BMI are poorly equipped to detect.

Testosterone runs on a separate but parallel track. Its decline through perimenopause is gradual, which makes it easy to overlook, but the structural consequences accumulate: reduced muscle mass and strength, and a progressive shift of fat towards the abdomen. Hot flushes and night sweats belong to the same hormonal picture — they arise because a destabilised oestrogen signal causes the hypothalamus, the brain's thermostat, to misread core body temperature and overreact.

Blood panels rather than scales offer the clearest read on this terrain. Tracking hormone levels, fasting glucose, and related markers — the kind of internal baseline Regeneration by Design is built around — makes visible what body composition measurements alone cannot. This is where Professor Paul Lee's Digital Body Bank concept becomes practically useful: a record of the body's internal environment over time, not just a snapshot of external form. For individual medical concerns, a healthcare professional should be the first point of call.

The longer-term chemistry stakes and the action window

Cardiovascular disease risk after perimenopause roughly doubles compared with premenopause — a figure that holds independent of age, meaning the transition itself carries chemical consequences for arterial health that extend well beyond the reproductive system. Oestrogen's stabilising role in vascular chemistry is established; when it is withdrawn, the vascular environment changes with it.

Bone tells a parallel story. Oestradiol levels correlate with bone mineral density at r = 0.46; among women five or more years past their final period, approximately 49% have osteopenia and 26% osteoporosis. That structural deterioration accumulates silently across the same years when perimenopause often goes unrecognised or unsupported.

Depression risk rises approximately 40% across the transition — a figure worth separating from the mood fluctuations already discussed. This is a distinct shift in psychiatric risk with a specific hormonal underpinning, not simply an extension of the week-to-week anxiety that hormonal volatility can produce.

None of these are inevitable outcomes. They are downstream consequences of a chemistry disruption that begins years before the final menstrual period — which is precisely what makes perimenopause the natural window for proactive support, rather than a phase to be endured and waited out.

This is the argument at the heart of Regeneration by Design: designing for healthspan means acting while the system is still responsive, not once visible damage makes waiting untenable. Professor Paul Lee's case for early, systemic intervention finds its clearest real-world expression here — the transition itself is the leverage point. For personal risk assessment, a healthcare professional remains the right first port of call.

Designing your chemistry through the transition

The science in the preceding sections maps onto four practical levers — each grounded in the mechanisms already described.

Nutrition: stabilise the internal environment. Because unstable oestrogen worsens insulin resistance beyond ageing alone, blood-sugar stability is a genuine priority. An anti-inflammatory dietary pattern, with phytoestrogens from soy isoflavones and flaxseed, may partially buffer oestrogen receptor activity during the transition — not a substitute for hormonal balance, but direct support for the internal chemistry under pressure.

Resistance training: where Physics meets Chemistry. Declining oestrogen and testosterone together erode muscle and bone; the oestradiol–BMD correlation (r = 0.46) confirms the loss is chemical in origin. Resistance training provides the mechanical load that stimulates bone remodelling through a separate route. Two to three sessions per week is sufficient to engage that effect.

Sleep as a non-negotiable. Progesterone loss degrades sleep architecture, hypothalamic instability adds vasomotor disruption, and declining melatonin compromises circadian timing from a third direction simultaneously. Consistent sleep and wake times, a cooler bedroom, and reduced blue light after dark each address at least one of those pathways — which is why sleep hygiene at this life stage is a physiological intervention, not a preference.

Bloodwork, not scales. The 2026 finding that ovarian decline impairs hepatic insulin signalling independently of body weight argues directly for monitoring the internal environment. A panel covering oestradiol, FSH, progesterone, and fasting insulin makes the body's chemistry legible in a way body composition measurements cannot — which is the central logic of Regeneration by Design: in Professor Paul Lee's framework, the internal environment is the environment that counts.

Beyond those four levers, the Regen PhD Pod's combination of timed heat, targeted light, and vibration works with two systems this transition specifically disrupts: temperature regulation and circadian signalling. As a non-medical wellness device, its role is relaxation and recovery support during a demanding physiological phase, not hormonal intervention.

A practical first step this week: commission a hormonal panel — oestradiol, FSH, and fasting insulin. One result tells you more about where your chemistry actually stands than months of scale-watching, and gives the design-first approach a real baseline to build from. A healthcare professional should guide any personalised hormonal assessment.

1. [1] Hormonal Changes During Menopause and Their Impact on Bone Health. (2025). https://doi.org/10.7759/cureus.93224 https://doi.org/10.7759/cureus.93224
2. [2] Sleep Disturbance and Perimenopause: A Narrative Review. (2025). https://doi.org/10.3390/jcm14051479 https://doi.org/10.3390/jcm14051479
3. [3] Perimenopause-induced insulin resistance via 5-HT dysregulation. (2026). https://doi.org/10.1042/CS20257657 https://doi.org/10.1042/CS20257657
4. [4] Estrogen and Metabolism: Navigating Hormonal Transitions from Perimenopause to Postmenopause. (2025). https://doi.org/10.4103/jmh.jmh_75_25 https://doi.org/10.4103/jmh.jmh_75_25
5. [5] Women's Midlife: A Nexus of Depression, Insulin Resistance, and Opportunity for Lifestyle Intervention. (2025). https://doi.org/10.1177/15409996251393035 https://doi.org/10.1177/15409996251393035
6. [6] In vivo brain estrogen receptor density by neuroendocrine aging. (2024). https://doi.org/10.1038/s41598-024-62820-7 https://doi.org/10.1038/s41598-024-62820-7
7. [7] Mental Health – An Emotional Roller Coaster Around Menopause. (2025). https://doi.org/10.55489/njcm.160120254670 https://doi.org/10.55489/njcm.160120254670